A review of its use as monotherapy and as combination therapy in the management of hypertension

Drugs

Volumn 70, Issue 15, 2010, Pages 2011-2049

  Duggan, Sean T ^a   Chwieduk, Claudine M ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Aliskiren, general; Hypertension

Indexed keywords

ACENOCOUMAROL; ALDOSTERONE; ALISKIREN; ALISKIREN PLUS AMLODIPINE; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; ALISKIREN PLUS VALSARTAN; ALLOPURINOL; AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ATENOLOL; ATORVASTATIN; CELECOXIB; CIMETIDINE; DIGOXIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; ITRACONAZOLE; KETOCONAZOLE; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; RIFAMPICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

ABDOMINAL PAIN; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLUENZA; MONOTHERAPY; NEPHROLITHIASIS; PERIPHERAL EDEMA; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; COMPARATIVE STUDY; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS;

AMIDES; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77957743506     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204360-000000000-00000     Document Type: Review

References (136)

1. Lawes CM, Vander Hoorn S, Rodgers A, et al. Global burden of blood-pressure-related disease, 2001. Lancet 2008 May 3; 371 (9623): 1513-1518
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28 (12): 1462-1536
3. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics: 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 Jan 29; 117 (4): e25-146
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-1252
5. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 (9455): 217-223
6. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008 Feb 5; 51 (5): 519-528
7. Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens 2006 Sep; 15 (5): 505-510
8. Crawford MH. Combination therapy as first-line treatment for hypertension. Am J Cardiovasc Drug 2009; 9 (1): 1-6
9. Sanoski CA. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009 Feb; 29 (2): 193-212
10. Novartis. Tekturna (aliskiren) tablets 150 mg and 300 mg: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ tekturna.pdf [Accessed 2010 Aug 23]
11. European Medicines Agency. Rasilez: summary of product characteristics [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document- library/EPAR- Product-Information/human/000780/WC500047010.pdf [Accessed 2010 Aug 23]
12. Novartis. Tekturna HCT- (aliskiren and hydrochlorothiazide tablets): US prescribing information [online]. Available from URL: http://www.pharma.us. novartis. com/product/pi/pdf/tekturna-hct.pdf [Accessed 2010 Aug 23]
13. European Medicines Agency. Rasilez HCT: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/ EPAR-Product-Information/human/000964/WC5000 47220.pdf [Accessed 2010 Aug 23]
14. Novartis. Valturna (aliskiren and valsartan, USP) tablets: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/ product/pi/pdf/ valturna.pdf [Accessed 2010 Aug 23]
15. Novartis. Tekamlo (aliskiren and amlodipine) tablets: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/ product/pi/pdf/tekamlo. pdf [Accessed 2010 Aug 31]
16. Baldwin CM, Plosker GL. Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension. Drugs 2009; 69 (7): 833-841
17. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67 (12): 1767-1792
18. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 Sep 5; 308 (4): 698-705
19. Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62 (13): 1983-2005
20. Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991 Mar; 41 (3): 478-505
21. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995 Sep; 50 (3): 560-586
22. Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007 Sep; 61 (9): 1461-1468
23. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007 Mar 20; 49 (11): 1157-1163
24. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial [published erratum appears in Lancet 2007 Nov 3; 370 (9598): 1542]. Lancet 2007 Jul 21; 370: 221-229
25. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007 Dec; 8 (4): 190-198
26. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 Jan; 25 (1): 217-226
27. Krone W, Hanefeld M, Meyer H-F, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens. Epub 2010 Apr 8
28. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004 Dec; 15 (12): 3126-3133
29. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002 Jan; 39 (1): E1-8
30. Azizi M, Menard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007 Sep 1; 2 (5): 947-955
31. Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008; 47 (8): 515-531
32. Iverson C, Christiansen S, Flanigan A. AMA manual of style: a guide for authors and editors. 10th ed. New York: Oxford University Press, 2007
33. Prescott MF, Wright M, Keefe DL, et al. Aliskiren, both as monotherapy and in combination with valsartan, reduces plasma aldosterone in patients with hypertension [abstract no. PP.24.457]. J Hypertens 2010 Jun; 28 e Suppl. A: e383
34. Gradman AH, Wright M, Keefe DL. Aliskiren-based treatment provides sustained reductions in blood pressure and plasma renin activity over 12 months in patients with hypertension [abstract no. P-31]. 24th Annual Scientific Meeting of the American Society of Hypertension; 2009 May 6; San Francisco (CA)
35. Andersen K, Weinberger MH, Constance CC, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2009; 10 (3): 157-167
36. Philipp T, Schmieder RE, Guerediaga J, et al. Aliskirenbased therapy provides long-term renin systemsuppression in patients with hypertension in a 52-week comparator trialwith hydrochlorothiazide-based therapy [abstract]. J Clin Hypertens (Greenwich) 2007 May; 9 (5 Suppl. A): 175-176
37. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008 Mar; 26 (3): 589-599
38. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009 Jan 27; 119 (3): 417-425
39. Fisher NDL, Danser AHJ, Nussberger J, et al. Renal and hormonal responses to direct renin inhibitionwith aliskiren in healthy humans. Circulation 2008 Jul 24; 117 (25): 3199-3205
40. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20
41. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006 Dec; 29 (12): 997-1005
42. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008 Sep; 9 (3): 163-175
43. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dosedependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 Mar 1; 111 (8): 1012-1018
44. Krop M, Garrelds IM, de Bruin RJ, et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008 Dec; 52 (6): 1076-1083
45. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48 (11): 1323-1338
46. Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007 Apr; 47 (4): 453-460
47. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006 Nov; 60 (11): 1343-1356
48. Vaidayanathan S, Jermany J, Yeh C, et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62 (6): 690-698
49. Limoges D, Dieterich HA, Yeh CM, et al. A study of doseproportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008 May; 46 (5): 252-258
50. Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007 Aug; 35 (8): 1418-1428
51. Zhao C, Vaidyanathan S, Yeh CM, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45 (11): 1125-1134
52. Vaidyanathan S, Zhao C, Yeh C, et al. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes. Clin Pharmacol Ther 2005; 79 Suppl.: 12
53. Bartlett M, Vaidyanathan S, Karan RS, et al. Multipledose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjects. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: 61-62
54. Vaidyanathan S, Warren V, Yeh C, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007 Feb; 47 (2): 192-200 (Pubitemid 46146485)
55. Vaidyanathan S, Bigler H, Yeh C-M, et al. Safety, tolerability and pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46 (8): 661-675
56. Huang HL, Vaidyanathan S, Yeh CM, et al. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. Curr Med Res Opin 2008 Sep; 24 (9): 2449-2456
57. Ayalasomayajula S, Tchaloyan S, Yeh CM, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008 Mar; 24 (3): 717-726
58. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005 Nov; 43 (11): 527-535
59. Vaidyanathan S, Maboudian M, Warren V, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 2008 Aug; 24 (8): 2313-2326
60. Urosevic D, Bartlett M, Costa Antunes AM, et al. Lack of pharmacokinetic interaction between aliskiren, a direct oral renin inhibitor, and isosorbide-5-mononitrate in healthy volunteers [abstract]. Basic Clin Pharmacol Toxicol 2007 Sep 1; 101 Suppl. 1: 63
61. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004 Oct; 58 (4): 433-436
62. Dieterich HA, Yeh C, Howard D, et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract no. PIII-78]. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: S110
63. Tapaninen T, Neuvonen PJ, NiemiM. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010 May; 66 (5): 497-502
64. Tapaninen T, Backman JT,KurkinenKJ, et al. Itraconazole, a p-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol. Epub 2010 Apr 23
65. Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OAT2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 2010 Sep; 88 (3): 339-342
66. European Medicines Agency. Rasilez HCT: European public assessment report [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/ EPAR-Public-assessment-report/human/000964/WC5000 47223.pdf [Accessed 2010 Aug 23]
67. Palatini P, Jung W, Shlyakhto E, et al. Maintenance of bloodpressure- lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2009May 21; 24 (2): 93-103
68. Verdecchia P, Calvo C, Mockel V, et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007; 16 (6): 381-391
69. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003 Dec; 42 (6): 1137-1143
70. BlumensteinM, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are nonresponsive to HCT 25mg alone. Curr Med Res Opin 2009; 25 (4): 903-910
71. Nickenig G, Simanenkov V, Lembo G, et al. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press 2008; 17 Suppl. 2: 31-40
72. Whaley-Connell A, Sowers J, Purkayastha D, et al. Combination therapy with aliskiren and HCTZ decreases plasma renin activity and oxidative stress vs ramipril while reducing blood pressure in obese patients with stage 2 hypertension [abstract no. PO-66]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A46
73. Geiger H, Barranco E, Gorostidi M, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens 2009 Jun; 11 (6): 324-332
74. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007 May; 49 (5): 1047-1055
75. Basile J, Babazadeh S, LillestolM, et al. First-line aliskiren/ hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in older patients with stage 2 hypertension (ACTION study) [abstract no. PO-11]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A22
76. Black HR, Kribben A, Aguirre Palacios F, et al. Aliskiren as monotherapy or in combination with hydrochlorothiazide provides effective BP lowering in patients with systolic BP 160-180mm Hg (ACQUIRE study) [abstract no. PO-15] J Clin Hypertens 2010 Apr; 12 Suppl. 1 A24
77. Ferdinand K, Pool J, Weitzman R. Responses to aliskiren/ HCTZ versus amlodipine on peripheral and central blood pressure in African American patients with stage 2 hypertension. J Am Coll Cardiol 2010 Mar 9; 55 (10 Suppl. 1): A61.E586
78. Zieve F, Yadao A, Yurkovic C, et al. Aliskiren with or without hydrochlorothiazide lowers blood oressure effectively in patients with stage 2 hypertension and metabolic syndrome [abstract no. PP.38.505]. J Hypertens 2010; 28 eSuppl. A: e600
79. Townsend RR, Forker A, Rumpelt P, et al. Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus [abstract no. LB-PO- 03]. J Clin Hypertens 2010; 12 (7): 534
80. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interimanalysis. Curr Med Res Opin 2008 Apr; 24 (4): 1039-1047
81. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009 Apr 25, 4; 951-959
82. Drummond W, Munger MA, Rafique Essop M, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007 Oct; 9 (10): 742-750
83. Black H, Weinberger M, Purkayastha D, et al. Combination aliskiren/amlodipine is more effective than amlodipine monotherapy in male and female African American subjects with stage 2 hypertension [abstract no. PO-20]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A26
84. Braun-Dullaeus RC, Zhang J, Hristoskova S, et al. Firstline therapy with aliskiren/amlodipie combination provides robust blood pressure reductions in patients with moderate to severe hypertension [abstract no. PO-22]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A27
85. Murray A, Koenig W, Garcia-Puig J, et al. Long-term therapy with aliskiren/amlodipine/hydrochlorothiazide combination provides effective blood pressure reduction with good tolerability in patients with moderate-to-severe hypertension [abstract no. PO-54]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A41
86. Kushiro T, Itakura H, Abo Y, et al. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res 2009 Mar; 32 (3): 169-175
87. Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2010; 24 (9): 600-608
88. Sica D, Gradman A, Lederballe O, et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BPlowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension [abstract no. P797]. Eur Heart J 2006 Sep; 27 Suppl.: 121. Plus poster presented at the World Congress of Cardiology; 2006 Sep 2-6; Barcelona
89. Novartis. Study to evaluate the efficacy and safety of aliskiren alone and in combination with amlodipine in essential hypertension [ClinicalTrials.gov identifier NCT00739973]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Aug 31]
90. Dahlof B, Anderson DR, Arora V, et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension [abstract no. P-376]. J Clin Hypertens (Greenwich) 2007 May; 9 (5 Suppl. A): 157
91. Weir MR, Prescott MF, Bush C, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren in patients with diabetes, metabolic syndrome or obesity: a pooled analysis of 10 randomized trials [abstract no. P888]. Circulation 2008 Sep 16; 118 (12): 162
92. Stanton AV, Gradman AH, Schmieder RE, et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. Hypertension 2010; 55 (1): 54-60
93. Schmieder RE, Philipp T, Guerediaga J, et al. Aliskirenbased therapy lowers blood presure more effectively than hydrochlorothiazide-based therapy in patients with hypertension [abstract no. P-436]. J Clin Hypertens 2007 May; 9 (5 Suppl. A): 182
94. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978 Apr 15; 1 (8068): 795-797
95. Schmieder RE, Philipp T, Guerediaga J, et al. Aliskirenbased therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009 Jul; 27 (7): 1493-1501
96. Yarows SA, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008 Dec; 25 (12): 1288-1302
97. Basile J, Babazadeh S, Lillestol M, et al. First-line aliskiren/ hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in older patients with severe stage 2 hypertension (systolic BP 180- 190mmHg) (ACTION study) [abstract no. PO-12]
98. Basile J, Babazadeh S, Lillestol M, et al. First-line aliskiren/ hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in elderly patients with stage 2 hypertension (ACTION study) [abstract no. PO-13]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A23
99. Black HR, Aguirre Palacios F, Arango JL, et al. Aliskiren alone or in combinationi with hydrochlorothiazide lowers BP effectively in hispanic/latino patients with systolic BP 160-180mmHg (ACQUIRE study) [abstract no. PO- 16] J Clin Hypertens 2010 Apr; 12 Suppl. 1: A24
100. Whaley-Connell A, Purkayastha D, Rick Z, et al. Aliskiren and HCTZ in combination provides improved blood pressure control compared with ramipril in obese patients with stage 2 hypertension regardless of baseline systolic blood pressure [abstract no. PO-65]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A45
101. Izzo J, Weinberger M, Israel M, et al. Aliskiren/amlodipine combination reduces central blood pressure more than amlodipine alone in African Americans with stage 2 hypertension [abstract no. PO-38]. J Clins Hypertens 2010 Apr; 12 Suppl. 1: A34
102. Whaley-Connell A, Purkayastha D, Ricks Z, et al. Antihypertensive efficacy of combination aliskiren/HCTZ compared to ramipril monotherapy in obese stage 2 hypertensive patients stratified by age [abstract no. PO-68]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A47
103. Yarows SA, Oparil S, Patel S, et al. Initial use of the aliskiren/valsartan combination is more effective than either component monotherapy in hypertensive patients with diabetes [abstract no. PO-72]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A49
104. Yarows SA, Oparil S, Patel S, et al. Initial use of the aliskiren/valsartan combination is more effective than either component monotherapy in obese and non-obese hypertensive patients [abstract no. PO-73]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A49
105. Whaley-Connell A, Purkayastha D, Ricks Z, et al. Ethnic differences in response to combination aliskiren/HCTZ vs ramipril monotherapy in obese patients with stage 2 hypertension [abstract no. PO-67]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A46
106. Yarows SA, Oparil S, Patel S, et al. Initial use of combination aliskiren/valsartan ismore effective than either component monotherapy in elderly and non-elderly hypertensive patients [abstract no. PO-71]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A48
107. Braun-Dullaeus RC, Shustov SB, Alvarex C, et al. Firstline treatment with aliskiren/amlodipiine combination provides robust blood pressure reductions in patients with severe hypertension [abstract no. 9A.06]. J Hypertens 2010; 28 e-Suppl. A: e430
108. Whaley-Connell A, Purkayastha D, Ricks Z, et al. Combination therapy with aliskiren+HCTZ reduces 24 hour ambulatory blood pressure more effectively than ramipril in obese patients with stage 2 hypertension [abstract no. PO-69]. J Clin Hypertens 2010 Apr; 12 Suppl. 1: A47
109. Yarows SA, Oparil S, Patel S, et al. Aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in elderly and younger patients with hypertension. J Hypertens 2008; 26 Suppl. 1: 19
110. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 Jun 5; 358 (23): 2433-2446
111. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 Feb 3; 119 (4): 530-537
112. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24
113. Scirica BM, Morrow DA, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 2010; 31 (16): 1993-2005
114. Cleland JGF, Coletta AP, Buga L, et al. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOPAF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur J Heart Fail 2010; 12: 623-629
115. Novartis. Sixmonths efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality in patients with acute decompensated heart failure (ASTRONAUT) [ClinicalTrials.gov identifier NCT00894387]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Aug 23]
116. Novartis. Aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints (ALTITUDE) [ClinicalTrials.gov identifier NCT00549757]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Aug 23]
117. Novartis. Efficacy and safety of aliskiren and aliskiren/ enalapril combination onmorbi-mortality in patients with chronic heart failure (ATMOSPHERE) [ClinicalTrials. gov identifier NCT00853658]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Aug 23]
118. Weir MR. Providing end-organ protection with reninangiotensin system inhibition: the evidence so far. J Clin Hypertens 2006 Feb; 8 (2): 99-105
119. Palmer BF. Improving BP control with combined reninangiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. Am J Cardiovasc Drug 2008; 8 (1): 9-14
120. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207-1225
121. Whitworth JA. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21 (11): 1983-1992
122. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18 (6): 308-347
123. Baguet JP, Legallicier B, Auquier P, et al. Updated metaanalytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig 2007; 27 (11): 735-753
124. Yarows SA. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Rev Cardiovasc Ther 2010 Jan; 8 (1): 19-33
125. McMurray JJ, Pfeffer MA, Swedberg K, et al. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004 Nov 16; 110 (20): 3281-3288
126. Zannad F,MatzingerA, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996 Jul; 9 (7): 633-643
127. Sica D, Andersen K, Oh BH, et al. Effects of aliskiren on blood pressure and plasma renin activity persist after stopping treatment in patients with hypertension. J Clin Hypertens 2008 May; 10 (5 Suppl. A): 34-35
128. Verma S, Gupta MK, Holmes DT, et al. Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study [abstract no. 1134]. Circulation 2009; 120 (18 Suppl.): S453
129. Richter D, Mickel C, Acharya S, et al. Aliskiren-based treatment controls blood pressure independent of baseline plasma renin activity [abstract no. 9A.03]. J Hypertens 2010 Jun; 28 e-Suppl. A: e429
130. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drug 2007; 7 (6): 413-422
131. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007 Aug; 120 (8): 713-719
132. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2003 Dec; 42 Suppl. 1: S87-91
133. Weintraub HS, Rudolph A. Combination therapy formanaging difficult-to-treat patients with stage 2 hypertension: focus on valsartan-based combinations. Am J Ther. Epub 2010
134. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009 Nov; 361 (22): 2153-2164
135. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16; 372 (9638): 547-553
136. ClinicalTrials.gov. Available from URL: http://www.clini caltrials.gov [Accessed 2010 Jul 2]